KPRX (Kiora Pharmaceuticals) Tariff Resilience Score: 6/10 (As of Jun. 30, 2026)


KPRX Kiora Pharmaceuticals Inc KPRX
32 GF Score
Price $2.63
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Tariff Resilience Score?

Kiora Pharmaceuticals KPRX +1.74% 32 Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus rates KPRX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,375 Biotechnology companies, Kiora Pharmaceuticals ranks better than 76% on this metric.

Kiora Pharmaceuticals has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Kiora Pharmaceuticals has Pharmaceuticals often face exemptions, but supply chain dependencies on international raw materials pose risks. Mitigation through alternative sourcing is possible.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Kiora Pharmaceuticals might have Average Resilient.

Kiora Pharmaceuticals  (NAS:KPRX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Kiora Pharmaceuticals Tariff Resilience Score Related Terms

KPRX vs PHIO, PBM, OSRH: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Kiora Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiora Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Tariff Resilience Score falls into.


KPRX
32GF Score
Kiora Pharmaceuticals Inc KPRX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Kiora Pharmaceuticals (KPRX) has a Tariff Resilience Score of 6 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Kiora Pharmaceuticals ranks #330 out of 1375 companies in the Biotechnology industry, placing it in the top 24%.
Is Kiora Pharmaceuticals' Tariff Resilience Score too high?
Kiora Pharmaceuticals' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Kiora Pharmaceuticals' value of 6 is 50% above this industry median. Based on the distribution chart, Kiora Pharmaceuticals ranks #330 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kiora Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Tariff Resilience Score compare to PHIO and PBM?
According to the Biotechnology industry distribution chart, Kiora Pharmaceuticals ranks #330 out of 1375 companies for Tariff Resilience Score. This places Kiora Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Kiora Pharmaceuticals' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiora Pharmaceuticals's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiora Pharmaceuticals's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Kiora Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
32GF Score

Get the complete analysis for KPRX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.63
Price